Elevated suPAR levels have been consistently associated with accelerated biological aging, increased risk of disease, greater disease severity, and higher mortality risk. These findings have been demonstrated across both healthy populations and various disease groups, with more than one million tests conducted to date.
suPAR plays an important role in immune activation and systemic inflammation, which has made it a valuable tool for predicting disease progression and guiding treatment strategies. It is also the first biomarker to be approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for guiding treatment decisions in infectious diseases.
In recent years, suPAR has become increasingly relevant in the fields of early disease detection, preventive health, and longevity for the following reasons:
- Higher suPAR levels are associated with faster biological aging, and the marker can predict the onset of common chronic diseases such as type 2 diabetes, cardiovascular disease, and cancer in the general population.
- Studies show that lifestyle improvements can lead to lower suPAR levels, which in turn are associated with reduced health risks.
- suPAR is now recognized not just as a marker but also as a causal factor in the development of age-related diseases, including atherosclerosis and chronic kidney disease, highlighting the importance of maintaining low suPAR levels as part of a long-term health strategy.
suPAR is the central biomarker used in all of Supar Health's services. The test is performed using suPARnostic®, a patented and CE-IVD approved technology that is validated for use in clinical decision-making.
Loading reports...